Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Interventional × Alpelisib × Clear all

Phase

Phase 1 28 Phase 2 26 Phase 1/2 10 Phase 3 9 Phase NA 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1

Interventions

Cisplatin 83 Fluorouracil 56 Gemcitabine 55 Paclitaxel 54 Docetaxel 54 Oxaliplatin 53 Capecitabine 53 Carboplatin 52 Cyclophosphamide 51 Radiotherapy 43 Drug Therapy 43 pembrolizumab 34 Leucovorin 31 Bevacizumab 31 Doxorubicin 29 Magnetic Resonance Spectroscopy 25 Dexamethasone 25 Cytarabine 24 Etoposide 23 Nivolumab 22 Pemetrexed 21 Methotrexate 21 Radiation 18 Vincristine 16 Trastuzumab 16 Irinotecan 16 apatinib 15 Prednisone 15 Letrozole 15 Folfox protocol 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05948943 2026-02-13

EPIK-L1

Novartis

Phase 2/3 Recruiting

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon ⚡